Home

Download

Statistics

Landscape

Help

Contact

	Gene summary
	Datasets with differential expression of this gene
	Expression of this gene in the resistant group across all datasets and cell types
	Significant ligand-receptor pairs related to this gene (This gene does not contain this module)
	Known drug resistance mechanisms of this gene (This gene does not contain this module)
	MicroRNAs (miRNAs) regulating this gene
	Motifs and transcription factors (TFs) regulating this gene
	Acts as a transcription factor (This gene does not contain this module)
	Acts as a drug target< (This gene does not contain this module)

Gene: PRRC2C

Summary for PRRC2C

Gene information	Gene symbol	PRRC2C
	Ensembl ID	ENSG00000117523
	Entrez ID	23215
	Gene name	proline rich coiled-coil 2C
	Synonyms	BAT2D1\|BAT2L2\|KIAA1096\|XTP2
	Gene type	protein_coding
	UniProtAcc	Q9Y520

Top

Dataset with differentially expressed gene: PRRC2C

Differentially expression genes between the resistant and sensitive groups. A positive avg_log2FC represents significantly high expression in the resistant group, while a negative avg_log2FC represents significantly low expression in the resistant group.

Dataset	Source	Tissue	Cancer type level1	Cancer type level2	Drug type	Regimen	Timepoint	Cell type	avg_log2FC	p_val_adj
GSE186960	Panc1 cell line	Cell line	Pancreatic cancer	Pancreatic ductal adenocarcinoma (PDAC)	Chemotherapy	gemcitabine	NA	Malignant cells	-0.399404	2.54e-31
GSE138267	CDX	Tumor tissue	Lung cancer	Small cell lung cancer (SCLC)	Chemotherapy	NA	NA	Malignant cells	0.588388	0.00e+00
GSE163836	FCIBC02 cell line	Cell line	Breast cancer	Inflammatory breast cancer	Chemotherapy	paclitaxel	NA	Malignant cells	0.307166	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	NK cells	0.281276	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	B cells	0.278637	5.56e-33
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	CD4+ T cells	0.347519	0.00e+00
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	NK cells	0.298493	7.94e-30
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	B cells	0.305479	6.47e-06
GSE153697	patients	Bone marrow aspirate	Acute lymphoblastic leukemia	Relapsed B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	anti-CD19 CAR-T	NA	Malignant cells	-0.27799	6.26e-08
GSE164551	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Immunotherapy	CAR-T	NA	CD4+ T cells	0.309565	2.04e-03
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Malignant cells	-0.642884	1.28e-29
GSE189460	patients	Bone marrow aspirate	Multiple myeloma	Multiple myeloma (MM)	Targeted therapy	bortezomib + melphalan + prednisolone	pre	Malignant cells	0.601231	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	CD8+ T cells	-0.688351	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	NK cells	-0.775696	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	CD4+ T cells	-0.771803	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	Malignant cells	-0.322476	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	Erythrocytes	-0.417498	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	Malignant cells	-0.310314	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	CD8+ T cells	-0.330102	1.00e-07
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	B cells	-1.01508	1.64e-03
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	CD4+ T cells	-0.320441	3.78e-03
GSE111014	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Chronic lymphocytic leukemia (CLL)	Targeted therapy	ibrutinib	post	CD8+ T cells	-0.291305	5.98e-17
GSE111014	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Chronic lymphocytic leukemia (CLL)	Targeted therapy	ibrutinib	pre	CD8+ T cells	-0.30667	3.89e-06
GSE131984_JQ1	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Targeted therapy	JQ1	NA	Malignant cells	-0.441654	1.16e-42
GSE131984_JQ1Pac	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Targeted therapy	JQ1 + paclitaxel	NA	Malignant cells	-0.427081	1.13e-23
GSE131984_JQ1Pal	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Targeted therapy	JQ1 + palbociclib	NA	Malignant cells	-0.607664	0.00e+00
GSE131984_Pal	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Targeted therapy	palbociclib	NA	Malignant cells	-0.395535	2.02e-21
GSE108397	451Lu cell line	Cell line	Melanoma	Melanoma	Targeted therapy	PLX-4720	NA	Malignant cells	-0.304677	0.00e+00
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	post	Erythrocytes	-0.481928	4.60e-04
GSE175716	PDX	Tumor tissue	Liver cancer	Advanced hepatocellular carcinoma	Targeted therapy	sorafenib	NA	Malignant cells	-0.424991	2.50e-34
GSE164897_VemCob	A375 cell line	Cell line	Melanoma	BRAFV600E-mutant melanoma	Targeted therapy	vemurafenib + combimetinib	NA	Malignant cells	0.539118	0.00e+00
GSE164897_VemTra	A375 cell line	Cell line	Melanoma	B+E2:E57RAFV600E-mutant melanoma	Targeted therapy	vemurafenib + trametinib	NA	Malignant cells	0.403179	0.00e+00

Top

Expression of PRRC2C in the resistant group across all datasets and cell types

Red dots represent significantly high expression in the resistant group, while blue dots represent significantly low expression in the resistant group. White dots represent that there is no significant difference in the expression of this gene between the resistant and sensitive groups. Blank represents that this cell type is not present in this dataset. (If the image exists, the user can click on it to enlarge it in a new window.)

Top

Significant ligand-receptor pairs related to PRRC2C

This table shows the significant ligand-receptor pairs related to this gene across all datasets, timepoints and conditions. (Complete files can be downloaded from the download section.)

Top

Known drug resistance mechanisms of this gene

This table shows the known drug resistance mechanisms of this gene. Clicking on this gene will link to another database that displays more drug resistance-related information.

Top

MicroRNAs (miRNA) regulating PRRC2C

This table shows the miRNAs with a score of more than 80 regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	miRNA	Score	GeneBank accession
PRRC2C	hsa-miR-190a-3p	100	NM_015172
PRRC2C	hsa-miR-5011-5p	100	NM_015172
PRRC2C	hsa-miR-3065-3p	96.5508	NM_015172
PRRC2C	hsa-miR-582-3p	95.9774	NM_015172
PRRC2C	hsa-miR-4774-5p	95.9244	NM_015172
PRRC2C	hsa-miR-3910	95.1352	NM_015172
PRRC2C	hsa-miR-338-3p	94.7175	NM_015172
PRRC2C	hsa-miR-3686	93.9761	NM_015172
PRRC2C	hsa-miR-3148	93.8998	NM_015172
PRRC2C	hsa-miR-1303	93.0308	NM_015172
PRRC2C	hsa-miR-3688-3p	93.0139	NM_015172
PRRC2C	hsa-miR-4262	92.7424	NM_015172
PRRC2C	hsa-let-7c-3p	92.6264	NM_015172
PRRC2C	hsa-miR-4530	92.219	NM_015172
PRRC2C	hsa-miR-548an	92.1408	NM_015172
PRRC2C	hsa-miR-3913-3p	91.5876	NM_015172
PRRC2C	hsa-miR-486-5p	91.5763	NM_015172
PRRC2C	hsa-miR-22-3p	91.5138	NM_015172
PRRC2C	hsa-miR-181d-5p	91.4692	NM_015172
PRRC2C	hsa-miR-181c-5p	91.4692	NM_015172
PRRC2C	hsa-miR-181b-5p	91.4692	NM_015172
PRRC2C	hsa-miR-181a-5p	91.4692	NM_015172
PRRC2C	hsa-miR-541-5p	91.4204	NM_015172
PRRC2C	hsa-miR-3163	90.6783	NM_015172
PRRC2C	hsa-miR-607	89.7602	NM_015172
PRRC2C	hsa-miR-452-3p	89.7123	NM_015172
PRRC2C	hsa-miR-3671	88.7413	NM_015172
PRRC2C	hsa-miR-6083	88.4561	NM_015172
PRRC2C	hsa-miR-4257	88.1512	NM_015172
PRRC2C	hsa-miR-15b-5p	87.9314	NM_015172
PRRC2C	hsa-miR-16-5p	87.9314	NM_015172
PRRC2C	hsa-miR-15a-5p	87.9314	NM_015172
PRRC2C	hsa-miR-195-5p	87.9314	NM_015172
PRRC2C	hsa-miR-4427	87.5583	NM_015172
PRRC2C	hsa-miR-4687-3p	86.97	NM_015172
PRRC2C	hsa-miR-889-5p	86.4233	NM_015172
PRRC2C	hsa-miR-6795-5p	85.9284	NM_015172
PRRC2C	hsa-miR-6887-5p	85.9284	NM_015172
PRRC2C	hsa-miR-5586-5p	85.8122	NM_015172
PRRC2C	hsa-miR-29b-3p	85.4944	NM_015172
PRRC2C	hsa-miR-29c-3p	85.4944	NM_015172
PRRC2C	hsa-miR-29a-3p	85.4944	NM_015172
PRRC2C	hsa-miR-4777-5p	85.1164	NM_015172
PRRC2C	hsa-miR-3123	84.7715	NM_015172
PRRC2C	hsa-miR-8084	84.5102	NM_015172
PRRC2C	hsa-miR-4716-5p	84.368	NM_015172
PRRC2C	hsa-miR-1299	84.3634	NM_015172
PRRC2C	hsa-miR-3613-3p	83.7793	NM_015172
PRRC2C	hsa-miR-6838-5p	83.7493	NM_015172
PRRC2C	hsa-miR-497-5p	83.7493	NM_015172

Page: 1 2

Top

Motifs and transcription factors (TFs) regulating PRRC2C

This table shows the Motifs and transcription factors (TFs) regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	motif	TF_highConf
PRRC2C	transfac_pro__M00665	SP3 (directAnnotation).
PRRC2C	kznf__ZNF548_Imbeault2017_OM_RCADE	ZNF548 (directAnnotation).
PRRC2C	metacluster_196.3	NR1H4; NR2F6; PRDM14; ZNF264; ZNF264 (directAnnotation). HNF4A; HNF4G; NR1D1; NR1D1; NR1D1; NR1D2; NR1D2; NR1D2; NR1H2; NR1H2; NR1H2; NR1H3; NR1H3; NR1H3; NR1I2; NR1I2; NR1I2; NR2C1; NR2C2; NR2F2; NR2F6; PPARA; PPARA; PPARA; PPARD; PPARD; PPARD; PPARG; PPARG; PPARG; RARA; RARA; RARA; RARB; RARB; RARB; RORA; RORA; RORA; RORB; RORB; RORB; RORC; RORC; RORC; RXRA; RXRB; RXRG; THRA; THRA; THRA; VDR; VDR; VDR (inferredBy_Orthology).
PRRC2C	kznf__ZNF2_Imbeault2017_OM_RCADE	ZNF2 (directAnnotation).
PRRC2C	taipale_tf_pairs__TFAP2C_HES7_NNCRCGYGNNNNNNSCCNNNGGS_CAP_repr	HES7; TFAP2C (directAnnotation).
PRRC2C	transfac_pro__M07329	SP7 (directAnnotation).
PRRC2C	taipale_tf_pairs__ETV5_TCF3_RNCGGAAGNNNNNCASSTGN_CAP_repr	ETV5; TCF3 (directAnnotation).
PRRC2C	metacluster_126.4	ZNF12; ZNF12; ZNF44; ZNF563; ZNF93 (directAnnotation).
PRRC2C	taipale__YY2_DBD_NNCCGCCATNW_repr	YY2 (directAnnotation).
PRRC2C	metacluster_141.2	E2F2; E2F3 (directAnnotation).
PRRC2C	metacluster_166.2	ELK4; ETS1; ETS1; ETV1; ETV3; ETV4; ETV5; ETV7 (directAnnotation). GABPA (inferredBy_Orthology).
PRRC2C	jaspar__MA1935.1	FOXI1 (directAnnotation).
PRRC2C	metacluster_166.5	ERG; ETV2; FLI1 (directAnnotation).
PRRC2C	metacluster_111.6	GMEB1; GMEB2 (directAnnotation).
PRRC2C	taipale_tf_pairs__ERF_FOXI1_TGTTKMCGGAWRN_CAP_repr	ERF; FOXI1 (directAnnotation).
PRRC2C	taipale_tf_pairs__ELK1_FOXI1_RSCGGATGTKKN_CAP	ELK1; FOXI1 (directAnnotation).
PRRC2C	metacluster_183.4	ETS1 (inferredBy_Orthology).
PRRC2C	transfac_pro__M06715	ZNF331 (directAnnotation).
PRRC2C	transfac_pro__M06273	ZNF766 (directAnnotation).
PRRC2C	transfac_pro__M00655	ETV4 (directAnnotation).
PRRC2C	metacluster_35.5	ELF1; ELF2; ELF3; ELF3; ELK1; ELK4; ERF; ERG; ETS1; ETS1; ETS2; ETV7; ETV7; FLI1; FLI1 (directAnnotation).
PRRC2C	taipale_tf_pairs__HOXB2_ETV1_ACCGGAAATGA_CAP	ETV1; HOXB2 (directAnnotation).
PRRC2C	metacluster_195.2	EGR2; KLF10; KLF10; KLF11; KLF11; KLF11; KLF13; KLF13; KLF13; KLF13; KLF13; KLF14; KLF14; KLF14; KLF14; KLF14; KLF15; KLF15; KLF16; KLF3; KLF8; KLF9; KLF9; KLF9; SP1; SP1; SP1; SP3; SP3; SP4; SP8; SP8; SP8; SP9; SP9 (directAnnotation). EGR1; KLF1; KLF12; KLF13; KLF14; KLF14; KLF14; KLF14; KLF14; KLF14; KLF16; KLF17; KLF17; KLF17; KLF17; KLF18; KLF18; KLF18; KLF18; KLF18; KLF18; KLF2; KLF2; KLF2; KLF3; KLF4; KLF5; KLF5; KLF5; KLF6; KLF7; KLF7; KLF8; KLF9; SP1; SP3; SP4; SP4; SP5; SP5; SP5; SP6; SP7; SP8; SP9 (inferredBy_Orthology).
PRRC2C	metacluster_35.2	EGR1; ELF1; ELF1; ELF1; ELF2; ELF2; ELF3; ELF4; ELF4; ELK1; ELK3; ELK4; ERG; ETS1; ETS1; ETS2; ETV1; ETV1; ETV5; ETV5; ETV6; FLI1; FLI1; GABPA; GABPA; GABPA; GABPB1; GABPB1; GABPB1; ZBTB7A (directAnnotation). ELF2; ELF2; ERG; ERG; ETS2; FLI1; GABPA; IKZF3; SPIC (inferredBy_Orthology).
PRRC2C	taipale_tf_pairs__GCM1_ETV1_RTRNNGGCGGAAGTN_CAP	ETV1; GCM1 (directAnnotation).
PRRC2C	tfdimers__MD00441	OVOL2; RELA (directAnnotation).
PRRC2C	metacluster_163.1	KLF1; KLF1; KLF1; KLF1; KLF1; KLF1; KLF1; KLF10; KLF10; KLF12; KLF12; KLF12; KLF13; KLF16; KLF17; KLF2; KLF3; KLF3; KLF3; KLF3; KLF4; KLF4; KLF4; KLF4; KLF4; KLF5; KLF5; KLF5; KLF5; KLF6; KLF6; KLF6; KLF7; KLF9; KLF9; SALL4; SP1; ZNF148; ZNF148; ZNF526 (directAnnotation). EGR4; KLF1; KLF1; KLF12; KLF12; KLF12; KLF13; KLF14; KLF14; KLF14; KLF14; KLF14; KLF14; KLF16; KLF17; KLF17; KLF17; KLF17; KLF17; KLF18; KLF18; KLF18; KLF18; KLF18; KLF18; KLF2; KLF2; KLF3; KLF4; KLF4; KLF4; KLF4; KLF4; KLF4; KLF5; KLF5; KLF5; KLF6; KLF7; KLF7; KLF8; KLF8; KLF9; SP4; SP5; SP5; SP6; SP7; SP8; SP9; ZNF526 (inferredBy_Orthology).
PRRC2C	metacluster_24.5	ZNF675; ZNF675 (directAnnotation).
PRRC2C	transfac_pro__M06173	ZNF85 (directAnnotation).
PRRC2C	hdpi__ETS1	ETS1 (directAnnotation).
PRRC2C	transfac_pro__M06259	ZNF91 (directAnnotation).
PRRC2C	transfac_pro__M06073	ZNF749 (directAnnotation).
PRRC2C	metacluster_156.3	DBP; DBP; DBP; DBP; DBP; DBP; DBP; DBP; HLF; HLF; HLF; HLF; HLF; HLF; HLF; NFIL3; NFIL3; NFIL3; NFIL3; NFIL3; NFIL3; NFIL3; TEF; TEF; TEF; TEF; TEF (directAnnotation). DBP; DBP; DBP; DBP; DBP; HLF; HLF; HLF; HLF; HLF; NFIL3; NFIL3; NFILZ; NFILZ; TEF; TEF; TEF; TEF (inferredBy_Orthology).
PRRC2C	transfac_public__M00040	ATF2 (directAnnotation).
PRRC2C	kznf__ZNF124_Imbeault2017_RP_RCADE	ZNF124 (directAnnotation).
PRRC2C	transfac_pro__M06724	ZNF331 (directAnnotation).
PRRC2C	taipale_tf_pairs__ELK1_EOMES_RSCGGAANNAGGYGYNA_CAP_repr	ELK1; EOMES (directAnnotation).
PRRC2C	swissregulon__hs__ELK1	ELK1 (directAnnotation).
PRRC2C	taipale_tf_pairs__ELK1_HOXA1_RCCGGAAGTAATTA_HT	ELK1; HOXA1 (directAnnotation).
PRRC2C	taipale_tf_pairs__MEIS1_ELF1_NTGCCGGAAGTN_CAP_repr	ELF1; MEIS1 (directAnnotation).
PRRC2C	dbtfbs__ZNF121_HEK293_ENCSR224QDY_merged_N3	ZNF121 (directAnnotation).
PRRC2C	taipale_tf_pairs__ETV2_HES7_RSCGGAANNNNNNNCACGTGNN_CAP_repr	ETV2; HES7 (directAnnotation).
PRRC2C	taipale_tf_pairs__ETV5_HOXA13_NNCGGAWGTNRTWAA_CAP	ETV5; HOXA13 (directAnnotation).
PRRC2C	transfac_pro__M04748	GABPA (directAnnotation).
PRRC2C	transfac_pro__M05838	ZNF550 (directAnnotation).
PRRC2C	taipale_tf_pairs__ERF_CEBPD_RSMGGAANTTGCGYAAN_CAP	CEBPD; ERF (directAnnotation).
PRRC2C	jaspar__MA1708.1	ETV7 (directAnnotation).
PRRC2C	taipale_tf_pairs__ETV2_RFX5_NNNTTCCGSNNNNGCAACNN_CAP_repr	ETV2; RFX5 (directAnnotation).
PRRC2C	taipale_tf_pairs__HOXB2_ELF1_SMGGAAGTMRTTA_CAP	ELF1; HOXB2 (directAnnotation).
PRRC2C	taipale_tf_pairs__HOXB2_ELK1_TAATKRCCGGAAGNN_CAP_repr	ELK1; HOXB2 (directAnnotation).

Page: 1 2 3 4 5 6

Top

Acts as a transcription factor

This table shows that this differential gene acts as a transcription factor.

Top

Acts as a drug target

This table shows that this differential gene acts as a drug target.

1	"Sun X, Zhang Y, Li H, Zhou Y, Shi S, Chen Z, He X, Zhang H, Li F, Yin J, Mou M, Wang Y, Qiu Y, Zhu F. DRESIS: the first comprehensive landscape of drug resistance information. Nucleic Acids Res. 2023 Jan 6;51(D1):D1263-D1275. doi: 10.1093/nar/gkac812. PMID: 36243960; PMCID: PMC9825618."
2	"Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037. PMID: 29126136; PMCID: PMC5753335."